Eli Lilly's Oral GLP-1 Candidate Orforglipron Advances in Approval Pathway

Eli Lilly's oral GLP-1 compound orforglipron is advancing toward regulatory approval, positioning itself as a potential advantage over Novo Nordisk's oral semaglutide (Rybelsus).